Accuracy and progress in the analytics of pharmaceuticalization: a response to Davis (2014).
This commentary considers the important contribution to understanding pharmaceuticalization made by Davis's (2014) case study of cancer drug treatment in end-of-life-care. However, it argues that Davis (2014) has misunderstood some aspects of the conceptual and analytical framework put forward by Abraham (2010) as a way of explaining the nature and implications of pharmaceuticalization.